Nurix Therapeutics, Inc.
Developing protein degradation medicines to treat cancer and autoimmune diseases.
NRIX | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 1700 OWENS STREET, SUITE 205, 94158 SAN FRANCISCO
- Website:
- https://www.nurixtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of medicines that control cellular protein levels. The company's core focus is on targeted protein degradation, utilizing the body's natural ubiquitin-proteasome system to eliminate disease-causing proteins. Its proprietary drug discovery engine, DEL-AI, powers a multi-modal pipeline of novel therapies, including small molecule degraders and Degrader Antibody Conjugates (DACs). Nurix is advancing these candidates to treat a broad range of cancers and autoimmune diseases, translating the science of degradation into clinical progress.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Nurix Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nurix Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nurix Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
